Interpace Biosciences, Inc. (IDXG)

Market Cap	3.95M
Revenue (ttm)	46.93M
Net Income (ttm)	7.17M
Shares Out	4.40M
EPS (ttm)	0.39
PE Ratio	2.19
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	228
Average Volume	2,401
Open	0.8982
Previous Close	0.8504
Day's Range	0.8982 - 0.8982
52-Week Range	0.5200 - 3.5400
Beta	0.55
RSI	32.61
Earnings Date	Mar 7, 2025

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic cancer; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expre...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1986
• Employees: 108
• Stock Exchange: OTCMKTS
• Ticker Symbol: IDXG

Financial Performance

In 2024, Interpace Biosciences's revenue was $46.93 million, an increase of 16.69% compared to the previous year's $40.21 million. Earnings were $7.17 million, an increase of 793.52%.